ECPAS-Mediated Proteasome Remodeling as a Mechanism of Resistance to Proteasome Inhibition in Multiple Myeloma

Název projektu anglicky
ECPAS-Mediated Proteasome Remodeling as a Mechanism of Resistance to Proteasome Inhibition in Multiple Myeloma
Anotace anglicky
Proteasome inhibitors (PIs) bortezomib and carfilzomib are cornerstone treatments for multiple myeloma (MM). However, resistance to PIs remains a major challenge in MM therapy. PI-resistant MM cells exhibit altered proteasome composition, including increased expression of the core 20S subunit, enhanced β2 subunit activity, and dynamic associations between the 20S subunit and regulatory subunits (19S or 11S). Our data show that PI-resistant MM is highly dependent on ECPAS, a proteasome scaffold and adaptor protein involved in regulating proteasome stability, complexity, and localization. However, its precise role in MM resistance to PIs remains unclear. Using biochemical and proteomic approaches, combined with functional cell assays and live-cell proteasome tracking, we will characterize the role of ECPAS in proteasome remodeling and redistribution in the context of proteasome inhibition and resistance. Understanding these mechanisms and the dependency of MM cells on ECPAS will define new therapeutic strategies to overcome PI resistance in MM.

Kategorie VaV
ZV - Základní výzkum
OECD FORD - hlavní obor
30204 - Oncology
OECD FORD - vedlejší obor
10608 - Biochemistry and molecular biology
OECD FORD - další vedlejší obor
—
CEP - odpovídající obory <br>(dle <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">převodníku</a>)
CE - Biochemie<br>EB - Genetika a molekulární biologie<br>FD - Onkologie a hematologie

Důvěrnost údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Systémové označení dodávky dat
CEP26-GA0-GA-R
Datum dodání záznamu
4. 5. 2026

Podobné projekty(10)